Stock SMMT SUMMIT THERAPEUTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-06 pm EDT 		5-day change 1st Jan Change
8.13 USD +1.12% Intraday chart for Summit Therapeutics Inc. -25.55% +211.49%
Jun. 03 Sector Update: Health Care Stocks Steady Premarket Monday MT
Jun. 03 Stifel Adjusts Summit Therapeutics Price Target to $14 From $8, Maintains Buy Rating MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Summit Raises $200 Million; Also Expands License Territories for Ivonescimab
BU
Ivonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMA
BU
 Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy
BU
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC in China
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
BU
Summit Therapeutics to Host First Quarter 2024 Financial Results & Operational Progress Call on May 1, 2024
BU
Summit Therapeutics Appoints Dr. Mostafa Ronaghi, Renowned Executive and Genomicist, to its Board of Directors
BU
Summit Therapeutics to Present at the Stifel 2024 Targeted Oncology Forum
BU
Summit Therapeutics Inc. - Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
AQ
Promising Intracranial Anti-Tumor Activity and Safety Data for Ivonescimab in NSCLC Patients with Brain Metastases Featured at ELCC 2024
BU
Intracranial Anti-Tumor Activity and Safety of Ivonescimab in NSCLC Patients with Brain Metastases to be Featured at ELCC 2024
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Summit Therapeutics Inc. - SMMT
PR
Summit Therapeutics Inc. (SMMT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
BU
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2023
BU
Summit Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results and Operational Progress Call on February 20, 2024
AQ
Summit Therapeutics to Host Fourth Quarter & Full Year 2023 Financial Results & Operational Progress Call on February 20, 2024
BU
Summit Therapeutics to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SMMT Stock
  4. News Summit Therapeutics Inc.
  5. Press Releases